SINOVAC's Varicella Vaccine Receives Marketing Authorization in Argentina

BEIJING, June 9, 2025 — SINOVAC Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, announced that its live attenuated varicella vaccine, developed by SINOVAC (Dalian) Vaccine Technology Co., Ltd., has been granted marketing authorization by Argentina's National Administration of Drugs, Foods and Medical Technology (ANMAT).

SINOVAC's varicella vaccine is the first from China to achieve the World Health Organization (WHO) Prequalification. It is also the first in its category in China to incorporate Phase III efficacy data into its official labeling. The approval in Argentina follows previous registrations in Peru, Lebanon, Kenya, and Macau in China. As one of South America's most rigorous regulatory authorities, ANMAT's authorization further validates the vaccine's safety, efficacy, and quality control standards.

Extensive post-market clinical research has reinforced the vaccine's profile. A study published in early 2023 demonstrated that the co-administration of SINOVAC's varicella vaccine and its inactivated Hepatitis A vaccine, Healive®, in 1-year-old children showed no difference in immunogenicity or safety compared to separate administrations. 

In response to the global trend of varicella shifting toward older age groups where the disease is often more severe SINOVAC received approval for an age expansion in June 2024. The vaccine is now indicated for all individuals aged 12 months and older. 

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.

Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

For more information, please see the Company’s website at www.sinovac.com.